Sanofi to acquire Ablynx for €3.9bn
Choreograph / iStockphoto.com
Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Biopharmaceutical merger, biotech acquisition, cancer research, tucatinib, oncology development